Literature DB >> 21705658

Mechanism of von Willebrand factor scissile bond cleavage by a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13).

Yaozu Xiang1, Rens de Groot, James T B Crawley, David A Lane.   

Abstract

The platelet-tethering function of von Willebrand factor (VWF) is proteolytically regulated by ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), which cleaves the Tyr1605-Met1606 (P1-P1') bond in the VWF A2 domain. To date, most of the functional interactions between ADAMTS13 and VWF that have been characterized involve VWF residues that are C terminal to the scissile bond. We now demonstrate that the substrate P3 position in VWF, Leu1603, is a critical determinant of VWF proteolysis. When VWF Leu1603 was substituted with Ser, Ala, Asn, or Lys in a short VWF substrate, VWF115, proteolysis was either greatly reduced or ablated (up to 400-fold reduction in k(cat)/K(m)). As Leu1603 must interact with residues proximate to the Zn(2+) ion coordinated in the active center of ADAMTS13, we sought the corresponding S3 interacting residues. Substitution of 10 candidate residues in the metalloprotease domain of ADAMTS13 identified two spatially separated clusters centered on Leu198 or Val195 (acting with Leu232 and Leu274, or with Leu151, respectively), as possible subsites interacting with VWF. These experimental findings using the short VWF115 substrate were replicated using full-length VWF. It is hypothesized that VWF Leu1603 interacts with ADAMTS13 Leu198/Leu232/Leu274 and that Val195/Leu151 may form part of a S1 subsite. The recognition of VWF Leu1603 by ADAMTS13, in conjunction with previously reported remote exosites C terminal of the cleavage site, suggests a mechanism whereby the VWF P1-P1' scissile bond is brought into position over the active site for cleavage. Together with recently characterized remote exosite interactions, these findings provide a general framework for understanding the ADAMTS family substrate interactions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21705658      PMCID: PMC3136259          DOI: 10.1073/pnas.1018559108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  The ADAMTS13 metalloprotease domain: roles of subsites in enzyme activity and specificity.

Authors:  Rens de Groot; David A Lane; James T B Crawley
Journal:  Blood       Date:  2010-07-20       Impact factor: 22.113

2.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.

Authors:  G G Levy; W C Nichols; E C Lian; T Foroud; J N McClintick; B M McGee; A Y Yang; D R Siemieniak; K R Stark; R Gruppo; R Sarode; S B Shurin; V Chandrasekaran; S P Stabler; H Sabio; E E Bouhassira; J D Upshaw; D Ginsburg; H M Tsai
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

3.  High resolution crystal structure of the catalytic domain of ADAMTS-5 (aggrecanase-2).

Authors:  Huey-Sheng Shieh; Karl J Mathis; Jennifer M Williams; Robert L Hills; Joe F Wiese; Timothy E Benson; James R Kiefer; Margaret H Marino; Jeffery N Carroll; Joseph W Leone; Anne-Marie Malfait; Elizabeth C Arner; Micky D Tortorella; Alfredo Tomasselli
Journal:  J Biol Chem       Date:  2007-11-08       Impact factor: 5.157

4.  Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor.

Authors:  Xiaohui Zhang; Kenneth Halvorsen; Cheng-Zhong Zhang; Wesley P Wong; Timothy A Springer
Journal:  Science       Date:  2009-06-05       Impact factor: 47.728

5.  N-linked glycosylation of VWF modulates its interaction with ADAMTS13.

Authors:  Thomas A J McKinnon; Alain C K Chion; Alexander J Millington; David A Lane; Mike A Laffan
Journal:  Blood       Date:  2007-11-01       Impact factor: 22.113

6.  A novel binding site for ADAMTS13 constitutively exposed on the surface of globular VWF.

Authors:  Sara Zanardelli; Alain C K Chion; Evelyn Groot; Peter J Lenting; Thomas A J McKinnon; Mike A Laffan; Michelle Tseng; David A Lane
Journal:  Blood       Date:  2009-07-08       Impact factor: 22.113

7.  Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis.

Authors:  M Furlan; R Robles; B Lämmle
Journal:  Blood       Date:  1996-05-15       Impact factor: 22.113

Review 8.  Biochemistry and genetics of von Willebrand factor.

Authors:  J E Sadler
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

9.  An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF.

Authors:  Wouter Pos; James T B Crawley; Rob Fijnheer; Jan Voorberg; David A Lane; Brenda M Luken
Journal:  Blood       Date:  2009-12-23       Impact factor: 22.113

10.  Evidence that high von Willebrand factor and low ADAMTS-13 levels independently increase the risk of a non-fatal heart attack.

Authors:  J T B Crawley; D A Lane; M Woodward; A Rumley; G D O Lowe
Journal:  J Thromb Haemost       Date:  2008-01-11       Impact factor: 5.824

View more
  28 in total

1.  ADAMTS13 and von Willebrand factor interactions.

Authors:  Catherine B Zander; Wenjing Cao; X Long Zheng
Journal:  Curr Opin Hematol       Date:  2015-09       Impact factor: 3.284

Review 2.  Structure-function and regulation of ADAMTS-13 protease.

Authors:  X L Zheng
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

3.  Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura.

Authors:  Marie Scully; Paul Knöbl; Karim Kentouche; Lawrence Rice; Jerzy Windyga; Reinhard Schneppenheim; Johanna A Kremer Hovinga; Michiko Kajiwara; Yoshihiro Fujimura; Caterina Maggiore; Jennifer Doralt; Christopher Hibbard; Leah Martell; Bruce Ewenstein
Journal:  Blood       Date:  2017-09-14       Impact factor: 22.113

4.  Carboxyl terminus of ADAMTS13 directly inhibits platelet aggregation and ultra large von Willebrand factor string formation under flow in a free-thiol-dependent manner.

Authors:  Jialing Bao; Juan Xiao; Yingying Mao; X Long Zheng
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-12-19       Impact factor: 8.311

5.  Rearranging exosites in noncatalytic domains can redirect the substrate specificity of ADAMTS proteases.

Authors:  Weiqiang Gao; Jian Zhu; Lisa A Westfield; Elodee A Tuley; Patricia J Anderson; J Evan Sadler
Journal:  J Biol Chem       Date:  2012-06-15       Impact factor: 5.157

6.  Hyperglycemia repression of miR-24 coordinately upregulates endothelial cell expression and secretion of von Willebrand factor.

Authors:  Yaozu Xiang; Jijun Cheng; Dandan Wang; Xiaoyue Hu; Yi Xie; Jeremiah Stitham; Gourg Atteya; Jing Du; Wai Ho Tang; Seung Hee Lee; Kristen Leslie; Geralyn Spollett; Zejian Liu; Erica Herzog; Raimund I Herzog; Jun Lu; Kathleen A Martin; John Hwa
Journal:  Blood       Date:  2015-03-26       Impact factor: 22.113

7.  Conformational activation of ADAMTS13.

Authors:  Kieron South; Brenda M Luken; James T B Crawley; Rebecca Phillips; Mari Thomas; Richard F Collins; Louis Deforche; Karen Vanhoorelbeke; David A Lane
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-15       Impact factor: 11.205

Review 8.  Regulation of VWF expression, and secretion in health and disease.

Authors:  Yaozu Xiang; John Hwa
Journal:  Curr Opin Hematol       Date:  2016-05       Impact factor: 3.284

Review 9.  Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor.

Authors:  James T B Crawley; Rens de Groot; Yaozu Xiang; Brenda M Luken; David A Lane
Journal:  Blood       Date:  2011-06-29       Impact factor: 22.113

10.  Massively parallel enzyme kinetics reveals the substrate recognition landscape of the metalloprotease ADAMTS13.

Authors:  Colin A Kretz; Manhong Dai; Onuralp Soylemez; Andrew Yee; Karl C Desch; David Siemieniak; Kärt Tomberg; Fyodor A Kondrashov; Fan Meng; David Ginsburg
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.